Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Exp Hypertens. 2012;34(8):548-54. doi: 10.3109/10641963.2012.681724. Epub 2012 May 9.

The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting.

Author information

1
Clinical Development, Novartis Horsham Research Centre, Horsham, UK. drnitinbb@yahoo.co.uk

Abstract

The aim of this study was to assess the quality of reporting of harms in hypertension clinical trials identified from the Cochrane Database using the Consolidated Standards of Reporting Trials (CONSORT) extension for harms reporting. Forty-one hypertension trials were included in the study. On average trials reported less than half of the items recommended by the CONSORT extension for harms (mean 9.83 items; 95% confidence interval = 8.06, 11.60). Trialists need to address the perceived shortcomings in measurement, analysis, and reporting of harms data so that the available trial data can be considered as a balanced and reliable source of evidence.

PMID:
22571478
DOI:
10.3109/10641963.2012.681724
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center